drugset
drugset / Trial / NCT04912141

Prevention of Acute Kidney Injury in Patients With NSTEMI

NCT04912141 ↗

Phase 2 Terminated 29 enrolled Pharming Technologies B.V.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A randomized, double-blind, placebo-controlled, multi-center, phase 2 clinical study in patients with NSTEMI undergoing urgent coronary angiography. Approximately 220 patients with CKD and acute NSTEMI, who are scheduled for an urgent coronary angiography (within 72 hours after admission and/or diagnosis of NSTEMI).

Timeline

Start
2021-04-21
Primary completion
2023-04-28
Completion
2023-04-28

Outcome

Outcome not reported

Stopped (Business): “Lower than expected study enrolment rate. New strategic considerations.”

Drugs

EvaluationDrugModalityDoseRoute
Comparator recombinant human C1 inhibitor Protein / enzyme biologic 50 iu/kg Intravenous
Comparator recombinant human C1 inhibitor Protein / enzyme biologic 100 iu/kg Intravenous

Indications

myocardial infarction